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ABSTRACT
Melanoma is themost lethal formofhumanskincancer.However, only limitedchemotherapy is currentlyavailable for themetastatic stageof the
disease.Sincechemotherapy, radiationandsodiumarsenite treatmentoperatemainly through inductionof the intrinsicmitochondrial pathway,
a strongly decreasedmitochondrial function inmetastatic melanoma cells, could be responsible for low efficacy of the conventional therapy of
melanoma. Another feature of metastatic melanoma cells is their proinflammatory phenotype, linked to endogenous expression of the
inflammatory cytokines, such as TNFa IL6 and IL8, their receptors, and constitutive NF-kB- and STAT3-dependent gene expression, including
cyclooxygenase-2 (PTGS2/COX2). In the present study, we treatedmelanoma cells with immunological (monoclonal antibody against TNFa or
IL6), pharmacological (smallmolecular inhibitorsof IKKb–NF-kBandJAK2–STAT3)orgenetic (specificRNAi forCOX-2)agents that suppressed
the inflammatory response incombinationwith inductionofapoptosisviaTRAIL.Asa resultof thesecombined treatments, exogenousTRAILvia
interactionswithTRAIL-R2/R1 strongly increased levels of apoptosis in resistantmelanomacells. Thepresent studyprovidesnewunderstanding
oftheregulationofTRAIL-mediatedapoptosis inmelanomaandwill serveasthefoundationforthepotentialdevelopmentofanovelapproachfor
a therapy of resistant melanomas. J. Cell. Biochem. 112: 463–475, 2011.  2010 Wiley-Liss, Inc.
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S cientific observations indicate that the incidence of mela-noma has significantly increased over the last 40 years in
the USA and worldwide, especially among young Caucasian women.
The probability of an American developing melanoma jumped from
1 in 1,500 in 1960, to 1 in 68 in 2000, and is projected to increase to
1 in 50 by the year 2010 [Rigel et al., 1996; Rigel, 2002]. In the USA
approximately 60,000 new cases were diagnosed and 8,420 deaths
occurred in 2008 (ACS, 2008). To date, the most effective single-
agent chemotherapies for melanoma treatment are the alkylating
drugs dacarbazine and temozolomide [Gogas et al., 2007]. However,
advanced melanomas respond poorly to chemo- and radiotherapy
and no effective therapy exists to inhibit the metastatic spread
of this cancer [Perlis and Herlyn, 2004; Chin et al., 2006]. Numerous
epidemiological studies have assessed risk factors associated with
melanomas. Even though UV exposure has been identified as one
of the major risk factors, the general etiology of melanoma remains
unclear.
The tumor-promoting effects of inflammation, which could be
a result of microbial infection, strong physical or chemical injury,
and obesity, are now widely recognized [Coussens and Werb, 2002;
Karin et al., 2006]. The inflammatory cytokines, TNFa, IL1b IL6,
and IL8, produced by the tumor microenvironment affect the
development and progression of the early stage melanomas in
vivo by regulating the expression of specific genes, which controls
proliferation and cell survival. In addition, as a result of Darwinian
selection, metastatic cancer cells (including melanomas) also
acquired the proinflammatory phenotype that was linked with
endogenous NF-kB-directed gene expression of proinflammatory
cytokines, their corresponding receptors and, finally, with con-
stitutive expression and strong enzymatic activity of cycloox-
ygenase-2 (COX-2), one of the critical enzymes involved in the
inflammatory response directing prostaglandin synthesis [Subbar-
amaiah and Dannenberg, 2003; Karin, 2009]. There is also a link
between chronic inflammation and deficiency of mitochondrial
function, which was observed during cancer progression [Pelicano
et al., 2006], as well as in neurodegenerative diseases [Beal, 2004].
A deficiency of normal mitochondrial respiratory function, but
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to be one of the characteristic features of the inflammatory response
[Alexeyev et al., 2004] and might be frequently found in cancer
cells, which have a tendency to change their energetic metabolisms
from oxidative phosphorylation to oxidative glycolysis (‘‘Warburg
effect’’) [Pelicano et al., 2006]. This critical link between
inflammation and tumorigenesis presents further challenges for
treatment of melanoma as establishing a connection between
proinflammatory phenotype and suppression of apoptosis in
metastatic melanoma cells.
Since the identification of TRAIL in 1995, this cytokine has been
intensively investigated, due to its strong and specific antitumor
effects through induction of apoptosis. In contrast to Fas, surface
expression of TRAIL-Receptors is mostly restricted to cancer,
but not to normal cells. However, many melanoma cell lines
demonstrated resistance to TRAIL based on numerous protective
mechanisms including downregulation of the endogenous death
receptor gene expression and strong upregulation of antiapoptotic
protein expression [Schaefer et al., 2007; Ashkenazi et al., 2008].
Furthermore, the genetic background of such resistance may include
upregulation of gene expression of growth factors, cytokines,
and their corresponding receptors controlling general cell survival
and antiapoptotic activity.
The main goal of the present study is to further elucidate
the mechanism of TRAIL-resistance and to increase sensitivity to
TRAIL-induced apoptosis in metastatic melanoma cells by suppres-
sion of their proinflammatory response. This study is ultimately
aimed to translate the results to the clinic, where this investigation
could lead to much needed improvement of melanoma therapy.
Our former investigations demonstrated that ionizing radiation
upregulated death receptor (FAS, TRAIL-Receptor1/DR4, and
TRAIL-Receptor2/DR5) total and surface expression in human
melanoma cells and increased TRAIL/TRAIL-R-mediated apoptosis
[Ivanov et al., 2007]. In contrast, numerous investigations have
indicated profound antiapoptotic effects of active STAT3 in different
types of cancer cells, including melanomas [Ivanov et al., 2001;
Kusaba et al., 2007]. In the present study, we focused attention
on pharmacological, immunological or genetic inhibition of the
TNFa/TNFR–NF-kB–IL-6/IL-6R–STAT3 signaling cascade [Griven-
nikov and Karin, 2008] to further suppress expression of its target
proteins, including antiapoptotic cFLIP, Bcl-xL, Mcl-1, Survivin,
and COX-2 [Kreuz et al., 2001; Ivanov et al., 2003; Subbaramaiah
and Dannenberg, 2003; Fulda and Debatin, 2006], and protein
regulators of cell proliferation, including Cyclin D1 [Darnell, 2002;
Leslie et al., 2006]. We expect that as a result of such treatment,
exogenous TRAIL/TRAIL-R interactions will induce apoptosis in
death-ligand-resistant melanoma cells. Furthermore, we anticipate
that suppression of COX-2, which is highly expressed in metastatic
melanoma cells [Ivanov and Hei, 2006a], will be especially
important for upregulation of TRAIL-induced apoptosis.
MATERIALS AND METHODS
MATERIALS
Human Killer-TRAIL was purchased from Alexis. PI3K inhibitor
LY294002, IKK inhibitor BMS-345541, STAT3 inhibitor-6 S3I-201
(also known as NSC 74859) and ATM inhibitor KU-55933 were
purchased from Calbiochem.
CELL LINES
Normal human fibroblasts TIG-3 were obtained from the Health
Science Research Resource Bank (Osaka, Japan). TIG-3 fibroblasts
and human melanoma cell lines LU1205 (also known as 1205lu),
WM9, WM35, WM793, WM852 [Satyamoorthy et al., 1997], A375,
FEMX, and HHMSX were maintained in DMEM medium supple-
mented with 10% fetal bovine serum (FBS), L-glutamine, and
antibiotics.
FACS ANALYSIS OF DR5 AND FAS LEVELS
Surface levels of DR4, DR5, and Fas were determined by staining
with the PE-labeled mAbs from eBioscience and from BD
Biosciences. A FACS Calibur flow cytometer (Becton Dickinson)
combined with the CellQuest program was used to perform flow
cytometric analysis.
TRANSFECTION AND LUCIFERASE ASSAY
The NF-kB luciferase reporter containing two kB binding sites, and
the STAT-Luc reporter containing three repeats of GAS sites were
used to determine NF-kB and STAT transactivation, respectively, in
transiently transfected cell lines.
APOPTOSIS STUDIES
Cells were exposed to soluble TRAIL (50 ng/ml) alone or in
combination with cycloheximide (2mg/ml). Different variations
of combined treatment were used in the presence or in the absence of
specific inhibitors of signaling pathways followed by TRAIL
treatment. After treatment, cell nuclei were stained by PI. Apoptosis
was then assessed by quantifying the percentage of hypodiploid
nuclei using FACS analysis. An additional approach was Annexin-
FITC plus PI staining, which allowed us to distinguish apoptotic
and necrotic cells, was performed according to the manufacture’s
protocol (BD Pharmingen).
CLONOGENIC SURVIVAL ASSAY
Cells were exposed to sodium arsenite (1–5mM), to soluble TRAIL
(50 ng/ml) alone or in combination with CHX (1mg/ml), BMS-
345541 (10mM), STAT3 inhibitor-6 (50mM) alone or in combination
with TRAIL for 24 h. Treated cells (500/dish) were then placed in
duplicate on 10-cm dishes for analysis of clonogenic survival
12 days after treatment. Colonies were stained using crystal violet
solution. The percentage of colony-formation (in relation to values
for untreated control cells) was calculated.
WESTERN BLOT ANALYSIS
Total cell lysates (50mg protein) were resolved on SDS–PAGE,
and processed according to standard protocols. The monoclonal
antibodies used for Western blotting included: anti-b-Actin
(Sigma); anti-FLIP (NF6) (Axxora); anti-COX-2 (Cayman Chemical).
The polyclonal antibodies used included: anti-DR5 (Axxora);
anti-phospho-AKT (Ser473) and anti-AKT; anti-STAT3 and anti-
phospho-STAT3 (Tyr705) (Cell Signaling). The secondary Abs were
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conjugated to horseradish peroxidase; signals were detected using
the ECL system (Amersham).
EMSA
Electrophoretic mobility shift assay (EMSA) was performed for the
detection of NF-kB DNA-binding activity as previously described.
Ubiquitous NF-Y DNA-binding activity was used as an internal
control [Ivanov and Hei, 2004].
REAL-TIME PCR ANALYSIS OF MITOCHONDRIAL DNA
Mitochondrial mtDNA copy number was determined by real-time
PCR using SYBR Green detection on an Applied Biosystems 7300
Real-time PCR System (Applied Biosystems). Products amplified
were a 188-bp fragment of the nuclear encoded 18S rRNA gene and
a 171-bp fragment of the mtDNA encoded 12S rRNA gene. The
primers were as follows: 18S sense, GGAGTATGGTTGCAAAGCTG;
18S antisense, CGCTCCACCAACTAAGAACG; 12S sense, AGAA-
CACTACGAGCCACAGC; and 12S antisense, ACTTGCGCTTACTTTG-
TAGCC. All reactions were done in triplicate. PCR conditions were as
follows: 958C for 15min followed by 40 cycles at 958C for 30 s, 558C
for 30 s, and 728C for 30 s. Relative quantification of mtDNA/nDNA
ratio was determined by the comparative threshold cycle (CT)
method as described previously [Partridge et al., 2007].
OXYGEN CONSUMPTION
Oxygen consumption in intact cells was assayed as described
previously [Partridge et al., 2007]. Briefly, 1 107 cells were
suspended in 1.5ml of DMEM lacking glucose, and oxygen
concentration was assayed over 3min at 378C in a Hansatech
(MA) Clark’s oxygen electrode unit.
ELISA
Antibodies pairs used in sandwich ELISA for this study was all
commercially available. Kits to detect IL6 and TNFa were from
Invitrogen.
STATISTICAL ANALYSIS
Data were calculated as means and standard deviations. Compar-
isons of results between treated and control groups were made by the
Students’ t-test. A P-value of 0.05 or less between groups was
considered significant.
RESULTS
PARTIAL DEPLETION OF MITOCHONDRIAL DNA AND
DOWNREGULATION OF MITOCHONDRIAL FUNCTIONS IN
MELANOMA CELL LINES
Multiple cell functions, including programmed cell death, are
dependent on mitochondria. Consequently, numerous studies have
targeted mitochondria as a probable tool for cancer therapy
[Costantini et al., 2000; Fulda et al., 2010]. The biogenesis of
mitochondria and general mitochondrial functions in cancer cells
could be substantially different when compared to normal cells.
Substantial change of mitochondrial functions is also involved in
the proinflammatory response of the cells. A frequent suppression
of mitochondrial respiration in cancer cells might be regulated by
genetic mechanisms, depending on both mutations/deletions in
mtDNA targeting critical mitochondrial proteins and general
depletion (decreased copy number) of mtDNA [Pelicano et al.,
2006]. These specific features of mitochondriogenesis have not been
previously investigated in melanoma cells. What are the actual
levels of mtDNA copy number and mitochondrial respiration in
metastatic melanoma cells compared to normal cells?
To address this question, we used normal human embryonic
fibroblasts TIG-3, human melanocytes and several human mela-
noma lines representing different phases of cancer development:
WM35 is a radial-growth-phase melanoma cells; WM793 is a
vertical-growth-phase melanoma cells; LU1205 (also known as
1250lu) andWM9 aremetastatic melanoma cells. All four melanoma
lines have normal NRAS, but mutated BRAF (V600E). WM35
and WM9 express functional PTEN, endogenous inhibitor of PI3K–
AKT, while in WM793 cells PTEN expression is down-regulated;
finally in LU1205 cells PTEN is inactivated by mutation [Krasilnikov
et al., 2003; Satyamoorthy et al., 2003]. Additionally, we used
HHMSX and FEMX metastatic melanoma lines. FEMX cells have
normal BRAF and PTEN, while HHMSX cells have mutated BRAF
(V600E) [Krasilnikov et al., 2003; Ivanov and Hei, 2005].
Analysis of the mtDNA by real-time PCR in these cell lines
demonstrated a pronounced decrease in mtDNA copy numbers for
several melanoma lines (with exception for FEMX). Sequencing
mtDNA demonstrated increased levels of mutations in the D-Loop
region of mtDNA from HHMSX and FEMX melanoma cells.
However, these mutations were all previously reported polymorph-
isms (Fig. 1A). Importantly, oxygen consumption, the main
reflection of mitochondrial respiration, was substantially decreased
in all melanoma lines, besides FEMX, and was well correlated with
down-regulation of mtDNA content (Fig. 1A,B). These observations
suggested that a partial downregulation of mitochondrial function
might be based on depletion of mtDNA that resulted in a decrease
of mitochondrial gene expression and substantial changes of
mitochondriogenesis in the corresponding melanoma cells.
Downregulation of mitochondriogenesis in cancer cells might
also be correlated with decreased activity of the endogenous, ATP-
dependent, mitochondrial apoptotic pathway due to a deficiency
of ATP production by mitochondria. Additionally, upregulation of
AKT activity in melanoma cells based on increased surface
expression of growth factor receptor kinases, such as EGFR, IGF1R,
or FGFR, in concert with a downregulation of PTEN, an endogenous
inhibitor of the PI3K–AKT pathway, could also inhibit the
mitochondrial apoptotic pathway [Krasilnikov et al., 2003; Wu
et al., 2003; Pelicano et al., 2006]. Indeed, vertical-growth phase
WM793, metastatic LU1205 (with mutated PTEN), and WM9
melanoma cells were characterized by pronounced surface expression
of EGFR and substantial upregulation of the basal phospho-AKT
activity compared tomelanocytes and normal TIG-3 cells, while FEMX
melanoma cells (with normal PTEN and low surface EGFR levels)
only contained trace levels of active phospho-AKT (Fig. 1C,D).
Interestingly, the early melanoma WM35 cells still contained
pronounced levels of the active AKT that was phosphorylated via
alternative receptor kinases (different from EGFR).
Numerous investigations demonstrated a relative resistance of
normal human cells to low doses of sodium arsenite (1–5mM), while
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many types of cancer cells died after such treatment [Mathas et al.,
2003; Amadori et al., 2005] (Fig. 2A). The reason for this difference
between normal and cancer cells is still unclear. However, among
melanoma cell lines, a protective role for EGF/EGFR–PI3K–AKT
signaling pathway against cytotoxic effects of sodium arsenite,
which directly targeted mitochondria, was established [Ivanov and
Hei, 2005; Partridge et al., 2007]. Indeed, sodium arsenite (5mM)
induced higher levels of apoptosis only in FEMX cells (Fig. 2A)
that demonstrated the normal mitochondrial function and low
active AKT levels before treatment (Fig. 1B,C). In contrast, sodium
arsenite induced relatively low levels of apoptosis in LU1205
and WM9 cells (Fig. 2A,B), which were characterized by decreased
Fig. 1. Mitochondrial (mt) DNA content, mitochondrial respiration and AKT levels in human melanoma cell lines. A: Content of mitochondrial (mt) DNA was determined using
the real-time PCR as described in the Materials and Methods Section. Number of mutations in the D-loop of mtDNA is indicated. All of these mutations represent previously
reported polymorphisms. B: The rate of oxygen consumption for normal human fibroblasts TIG-3, human melanocytes and melanoma lines was determined using an oxygen
electrode unit. C: Western blot analysis of total and phospho-AKT levels in melanocytes, TIG-3 fibroblasts and indicated melanoma lines. D: Surface levels of EGFR and NGFR1
p75 in human melanoma cells were determined by immunostaining with anti-EGFR-PE and anti-NGFR1-PE mAbs using FACS analysis; n.s., nonspecific staining.
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mitochondrial respiration and high basal AKT activity before
treatment (Fig. 1B,C). Furthermore, sodium arsenite (5mM)
substantially decreased mitochondrial respiration in melanoma
cells, while normal human melanocytes were more resistant to
arsenite treatment. As expected, melanocytes and TIG-3 normal
fibroblasts were also relatively resistant to arsenite-induced
apoptosis (Fig. 2A,C and Suppl. Fig. 1C). Costimulation with EGF
(50 ng/ml) efficiently down-regulated arsenite-induced death of
LU1205 and WM9 melanoma cells, but not FEMX (Fig. 2B). On the
other hand, arsenite-induced cell death was substantially decreased
by zVAD-fmk, a universal caspase inhibitor, LEHD, a caspase-9
inhibitor, and IETD, a caspase-8 inhibitor, highlighting a role of
the activation of both the mitochondrial apoptotic pathway and
death receptor-mediated pathway after arsenite exposure (Fig. 2B).
In spite of high levels of nerve growth factor receptor-1 (NGFR1
p75) surface expression on WM35, WM793, LU1205, and WM9
melanoma cells (Fig. 1D), NGF-b (100 ng/ml) in the media did not
protect these cells against arsenite-induced killing indicating
attenuation of NGFR1-mediated signaling in the melanoma lines
used. (Fig. 2B). This was in contrast to the highly protective action
of NGF-b against arsenite-induced apoptosis in differentiated
neuron-like PC12 cells (Suppl. Fig. 1A,B) via AKT activation
[Kimmelman et al., 2000]. On the other hand, melanoma cells
displayed substantially increased cytotoxicity after sodium arsenite
treatment, as compared to apoptosis (Fig. 2D), suggesting the
involvement of necrotic mechanisms in sodium arsenite action.
Taken together, our data demonstrated a relatively low efficacy of
apoptotic pathways induced by sodium arsenite for specific killing
melanoma cells with decreased mitochondrial function and
permanently active AKT (most metastatic melanoma lines), but
highlighted a usefulness of such an approach for killing some
types of melanoma cells (FEMX) with non-suppressedmitochondrial
function and low levels of the basal AKT activity.
We also screened two additional metastatic melanoma cell lines
for sensitivity to arsenic. Surprisingly, A375 andWM852 melanoma
cells with very low basal AKT activity [Dhawan et al., 2002; Hilmi
et al., 2008] were sensitive to cytotoxic effects of sodium arsenite (5–
10mM), and thus were killed mostly through necrotic, rather than
apoptotic mechanisms (Suppl. Fig. 2). These data indicated that AKT
deficiency correlated with increased levels of arsenic-induced total
cell death (which could be driven either apoptotic or necrotic
mechanisms). Furthermore, inhibition of PI3K–AKT activity by
Fig. 2. The mitochondrial death pathway in human melanoma cell lines. A,B: Cell cycle-apoptosis analysis of melanocytes, FEMX, LU1205, and WM9 melanoma cells, which
were treated sodium arsenite (5mM) in the presence or absence of either NGF-b (100 ng/ml) or EGF (50 ng/ml) for the next 24 h; non-treated control cells were designed as
(Con). Caspase inhibitors, zVAD, LEHD, and IETD (50mM), were additionally used. After treatment, cells were stained with PI and analyzed by FACS assay. Error bars represent
mean SD (Student’s t-test, P< 0.05). C: Effects of sodium arsenite on oxygen consumption of melanocytes (M-cytes), FEMX and LU1205 melanoma cells 24 h after
treatment. D: Clonogenic survival assay of melanoma cell lines 12 days after sodium arsenite treatment.
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LY294002 strongly increases levels of arsenite-induced death in
resistant melanoma lines and unfortunately, also in TIG-3 normal
fibroblasts and neuron-like PC12 cells. Necrotic effects of arsenite
treatment were also increased in response to AKT inhibition (Suppl.
Fig. 1). Trying to avoid non-specific cytotoxicity linked to direct
targeting of mitochondria in normal cells, we refocused our
attention on other characteristic features of the proinflammatory
response in metastatic melanoma cells and their possible role in the
regulation of apoptosis.
PROINFLAMMATORY RESPONSE OF METASTATIC MELANOMA
CELLS AND REGULATION OF TRAIL-INDUCED APOPTOSIS:
A ROLE FOR NF-kB
Besides directly targeting mitochondria with different drugs and
natural compounds, stimulation of the death receptor-dependent
apoptotic pathways has been widely used for treatment of
melanoma cells. However, most metastatic melanoma cell lines
were relatively resistant to death ligands, FasL, and TRAIL.
Numerous observations demonstrated expression and secretion of
proinflammatory cytokines by cancer cells, including malignant
melanoma cells in culture and in vivo [Mattei et al., 1994;
Yurkovetsky et al., 2007]. We wondered whether cytokine-mediated
inflammatory signaling, which could perform many functions in
cell–cell communications, might also be involved in anti-apoptotic
protection of melanoma cells.
To address this question, we first determined levels of secretion of
TNFa and IL6, crucial proinflammatory cytokines, in cell media of
several melanoma lines using specific ELISA. WM9 metastatic
melanoma cells were characterized by high basal expression and
secretion of TNFa and IL6, while LU1205 metastatic melanoma cells
secreted substantially decreased levels of these cytokines 24 h after
refreshing cell media. On the other hand, the early phase WM35
melanoma cells produced modest levels of TNFa and zero levels of
IL6. Human melanocytes did not produce detectable levels of TNFa
and IL6 (Fig. 3C,D). Stress exposure, such as g-radiation at dose of 2–
5Gy, could notably upregulate IL6 secretion by WM9 cells (1.5- to
2.0-fold increase was detected 24 h after irradiation). Furthermore, a
high-level IL8 expression and secretion was previously observed in
WM9 cells [Peng et al., 2007].
Transcription factors NF-kB and STAT3 are the master regulators
of the proinflammatory response in cells at the level of cytokine
gene expression [Grivennikov and Karin, 2008; Yu et al., 2009]. As
expected, BMS-345541, an inhibitor of the IKKb–NF-kB pathway,
strongly decreased the nuclear NF-kB DNA-binding activity and
NF-kB-dependent transcription in general (Fig. 3A,B). It signifi-
cantly decreased the basal levels of secretion of TNFa and,
especially, IL6 in LU1205 and WM9 cells (Fig. 3C,D) that was
correlated with the critical role of NF-kB in TNF and IL6 gene
expression. TNFR1 surface levels were relatively high in LU1205
cells, establishing efficient NF-kB activating loop in these cells,
while WM9 cells exhibited substantially lower surface TNFR1 levels
(Fig. 3E). Furthermore, suppression of nuclear NF-kB activity
(Fig. 3A; EMSA), NF-kB transacting functions (Fig. 3B) and NF-kB-
target gene expression (Fig. 3A, Western data) by BMS-345541
(10mM) was accompanied by variable-level apoptosis (Fig. 3F). As a
result, almost 90% ofWM9 cells and 50% of LU1205 cells were killed
48 h after exposure to BMS-345541 (10mM), while the early
melanoma cells WM35 were relatively resistant.
Even though targeting NF-kB is an important tool for treatment
of some metastatic melanomas [Ivanov et al., 2000; Yang et al.,
2006, 2009], it appears not to be a universal approach for killing
melanoma cells. Our next task was to elucidate any additional
enhancing effects of IKKb–NF-kB suppression of the apoptotic
response induced by TRAIL in melanoma cell lines. Inhibition of NF-
kB activation and NF-kB target gene expression resulted in down-
regulation of anti-apoptotic protein levels, such as Bcl-xL, COX-2,
and Survivin (Fig. 3A), in concert with other numerous NF-kB
transcriptional targets. As a result, combined treatment with TRAIL
(30 ng/ml) and BMS-345541 (10mM) additively increased apoptotic
levels in LU1205 cells 24–48 h after exposure (Fig. 3F). Such
treatment after 48 h had no additional effects for WM9 cells that
were already very sensitive to both TRAIL and BMS-345541
exposure, while still enhanced apoptotic response in these cells 24 h
after treatment (Fig. 3F). WM35 cells with low sensitivity to TRAIL,
due to deficiency in surface DR5/DR4 expression (see Fig. 4B), did
not up-regulate levels of BMS-induced apoptosis in the presence of
TRAIL (Fig. 3F). Clonogenic survival assay further confirmed
additive effects of BMS-345541 and TRAIL for efficient killing
LU1205 and WM9 cells (Fig. 3G).
A ROLE FOR STAT3 IN ANTI-APOPTOTIC PROTECTION
It was well established that the NF-kB-dependent expression and
secretion of IL6 further activated the IL6/IL6R–JAK2–STAT3
pathway and STAT3-mediated gene expression via autocrine and
paracrine mechanisms in inflammatory and cancer cells [Karin,
2009; Yu et al., 2009]. To determine a role for STAT3 and STAT3-
transcriptional target genes in the regulation of apoptosis, we used
STAT3 inhibitor-6, S3I-201 (also known as NSC 74859) (Fig. 4A),
which worked through inhibition of STAT3 dimerization and
activation [Lin et al., 2009]. As expected, we observed dose-
dependent inhibition of STAT-reporter activity (Fig. 4A, the upper
panel), suppression of Tyr705 STAT3 phosphorylation and
decreased protein expression of COX-2, one of the STAT3
transcriptional targets following treatment with S3I-201
(Fig. 4A, the lower panel). WM9 cells were highly sensitive to
S3I-201, as evidenced by increased apoptosis, while LU1205 cells
demonstrated only pronounced changes in cell cycle distribution
(with G2/M and S-phase arrest) following exposure to this inhibitor
(Fig. 4C). WM9 and LU1205 cells exhibited pronounced DR5 surface
expression (Fig. 4B), but displayed quite different sensitivity to
TRAIL (Fig. 4C). On the other hand, levels of TRAIL-induced
apoptosis were further up-regulated by S3I-201 only in LU1205
cells, while a combination of TRAIL and S3I-201 induced high levels
of death of WM9 cells not only via apoptosis [that was relatively
stable at 66–61% (Fig. 4C)], but probably also by necrosis. Indeed, a
clonogenic survival assay demonstrated complete killing of WM9
cells by a combination of TRAIL and S3I-201 12 days after treatment
(Fig. 4D). The increased resistance of LU1205 to TRAIL-induced
apoptosis, compared to WM9 cells, was probably based on the
substantially higher levels of NF-kB activity in LU1205 cells (see
Fig. 3A).
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Fig. 3. A role of NF-kB for expression and secretion of TNFa and IL6 and regulation of TRAIL-induced apoptosis in human melanoma cell lines. A: Effect of an IKK-NF-kB
inhibitor BMS-345541 (10mM) on the NF-kB DNA-binding activity determined by EMSA. Position of two main DNA-binding complexes is shown. DNA-binding activity of the
ubiquitous transcription factor NF-Y was used as an internal control. Effect of BMS-345541 on expression levels of indicated proteins in LU1205 cells was determined by
Western blot analysis. B: Effect of an IKK-NF-kB inhibitor BMS-345541 (10mM) on 2xNF-kB-Luc reporter activity in transiently transfected melanoma cell lines. C,D: Effect of
BMS-345541 (10mM) on TNFa and IL6 secretion by human melanocytes (MC) and melanoma cell lines determined by ELISA. E: Surface expression of TNFR1 was determined by
immunostaining with anti-TNFR1-PE mAb and FACS analysis; n.s., nonspecific staining. F: Effects TRAIL (30 ng/ml) alone or in combination with BMS-345541 (10mM) on
apoptosis (24 and 48 h after exposure) in indicated melanoma lines. Apoptosis levels were determined, as described above. Error bars represent mean SD (Student’s t-test,
P< 0.05). G: Effects of TRAIL (30 ng/ml) and BMS-345541 (10mM) on clonogenic survival melanoma cell lines.
JOURNAL OF CELLULAR BIOCHEMISTRY INHIBITION OF INFLAMMATION AND TRAIL-INDUCED DEATH 469
Interestingly, treatment with a combination of inhibitors for both
IKK-NF-kB and STAT3 (BMS-345541 and S3I-301) demonstrated
additive effects for killing LU1205 48 h after treatment (Fig. 5A).
Furthermore, simultaneous inhibition of NF-kB and STAT3 notably
increased levels of TRAIL-induced apoptosis for resistant FEMX and
HHMSX cells (Fig. 5A). Taken together, these results further
confirmed a role for the transcriptional regulators, NF-kB and
STAT3, in suppression of TRAIL-induced apoptosis in melanoma
cells. As a complementary approach, we used monoclonal inhibitory
antibodies to block TNFa and IL6 transmission and to inhibit
aurocrine/paracrine stimulation of melanoma cells by these
cytokines, which further regulated NF-kB and STAT3 activation.
This resulted in pronounced upregulation of TRAIL-induced
apoptosis for WM793, LU1205, and WM9 cells after suppression
of TNFa or IL6 transmission (Fig. 5B,C). Furthermore, the
proapoptotic effect was especially strong after treatment with a
combination of both inhibitory antibodies (Fig. 5C). These data are
a direct demonstration of a protective role of TNFa and IL6 against
TRAIL-induced apoptosis in malignant melanoma cells.
A ROLE OF COX-2 FOR THE SUPPRESSION OF TRAIL-INDUCED
APOPTOSIS IN MELANOMA CELLS
NF-kB and STAT3 are direct transcriptional regulators of numerous
genes. Since one of the critical enzymatic regulators of the
inflammatory response, cyclooxygenase-2 (COX-2), was a tran-
scriptional target of both NF-kB and STAT3 [Kanekura et al., 2002;
Lo et al., 2010], we further focused our attention on the significance
of COX-2 in anti-apoptotic protection of human melanoma cells.
Suppression of STAT3 activity, as well as NF-kB activity, was indeed
accompanied by down-regulation of protein expression of COX-2
in LU1205 and WM9 melanoma cells (see Figs. 3A and 4A).
On the other hand, inhibition of COX-2 enzymatic activity by a
specific inhibitor NS398 (50mM) further increased TRAIL-induced
apoptotic levels in LU1205, WM9, and FEMX metastatic melanoma
cells, while demonstrating no additional effects in WM35, and
HHMSX melanoma cells, as well as in normal TIG-3 cells (Fig. 6A).
As we previously demonstrated [Ivanov et al., 2008], TIG-3, WM35,
and HHMSX cells possess low levels of DR5 surface expression
and negligible DR4 surface expression (see also Fig. 4D).
Fig. 4. Effects of STAT3 inhibition on melanoma cell apoptosis. A: Dose-dependent effect of STAT3 inhibitor-6 (S3I-201) on STAT-dependent luciferase activity. WM9 cells
were transiently transfected with 3xSTAT-Luc reporter and then treated for 6 h using S3I-201. Western blot analysis of phospho-Tyr705–STAT3 and COX-2 levels after 6-h
exposure with S3I-201. Actin was used as a loading control. B: Surface expression levels of DR5 were determined for indicated cell lines using with anti-DR5-PE mAb and flow
cytometry. C: Effects of S3I-201 (50mM) alone or in combination with TRAIL on cell cycle-apoptosis in LU1205 and WM9 melanoma cells. Results of a typical experiment are
presented (one from three). D: Clonogenic survival assay of LU1205 and WM9 cells 12 days after treatment with S3I-201 (50mM), TRAIL (30 ng/ml) or their combination.
Double star indicates zero survival of WM9 cells after combined treatment. Error bars represent mean SD (Student’s t-test, P< 0.05).
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Furthermore, pronounced downregulation of COX-2 protein
levels by COX-2 RNAi [Ivanov and Hei, 2006b] was also
accompanied by a decrease in cFLIP protein levels, a critical
inhibitor of caspase-8 activity, and the subsequent upregulation
of TRAIL-induced caspase-8-mediated apoptosis in LU1205 cells.
For TRAIL-sensitive WM9 cells, effects of COX-2 suppression were
also significant, but less pronounced (Fig. 6B). Downregulation
of COX-2 levels by specific RNAi was accompanied by increased
TRAIL-induced apoptosis in WM9 and LU1205 cells (Fig. 6C).
An important role of cFLIP, which by itself was a transcriptional
target of NF-kB and STAT3, in the negative regulation of TRAIL-
induced apoptosis in melanoma cells was reported previously
[Ivanov and Hei, 2006b]. Effect of pharmacological inhibition of
COX-2 on downregulation of cFLIP levels in cancer cell lines was
also previously reported [Liu et al., 2006]. Taken together, our results
confirmed that inhibition of COX-2 (as a STAT3 and NF-kB
transcriptional target in the inflammatory response) further
upregulated TRAIL-induced apoptosis in melanoma cells.
ADDITIONAL INHIBITORS OF PROINFLAMMATORY GENE
EXPRESSION, INCREASED THE SUSCEPTIBILITY OF MELANOMA
CELLS TO TRAIL
The polyphenolic phytoalexin, resveratrol (RSV), is an efficient
inhibitor of both NF-kB- and STAT3-dependent transcription in
melanoma lines as well as in different cancer cell lines in concert
with extensive activation of ATM-p53 and MAPK pathways
[Aggarwal et al., 2004; Ivanov et al., 2008]. Production and
secretion of TNFa and IL6, as well as protein expression of COX-2
(Fig. 7A–C) were substantially decreased by RSV treatment of
melanoma lines. RSV exposure also further decreased mitochondrial
respiration in cancer cells (Fig. 7D), similar to the effects of sodium
arsenite treatment (see Fig. 2). These data highlighted the general
anti-inflammatory effects of RSV in melanoma cells. RSV by
itself demonstrated only modest levels of melanoma cell killing
determined by decreased clonogenic survival following RSV
exposure (Fig. 7E). However, a combination of TRAIL and RSV
was extremely effective in the induction of high levels of cell death
Fig. 5. Double inhibition of NF-kB and STAT3: effects on TRAIL-induced
apoptosis. A: Cells were treated with BMS-345541 (10mM), S3I-201 (50mM),
TRAIL (30 ng/ml) individually or in combination. Apoptotic levels were deter-
mined using PI staining of DNA and flow cytometry. B,C: Effects of anti-TNFa
(aTNF) (5mg/ml), anti-IL6 (aIL6) (5mg/ml) mAbs or their combination
on TRAIL-induced apoptosis in melanoma cell lines. Error bars represent
mean SD (Student’s t-test, P< 0.05)
Fig. 6. Effects of downregulation of COX-2 on TRAIL-induced apoptosis.
A: Effects of NS398 (50mM), an enzymatic inhibitor of COX-2, on TRAIL
(30 ng/ml) or TRAILþ CHX (1mg/ml) induced apoptosis in fibroblasts and
indicated melanoma lines. B: Effects of COX-2 suppression by specific COX-2
RNAi on COX-2 and cFLIP-L protein expression levels in WM9 and LU1205
melanoma cells. Cell cultures stably transfected by control or COX-2 RNAi were
previously described. C: TRAIL-induced apoptosis in control and COX-2 defi-
cient cell cultures. Apoptotic levels were determined 48 h after treatment
using PI staining and the flow cytometry. Error bars represent mean SD
(Student’s t test, P< 0.05).
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in several melanoma lines based on results of a clonogenic survival
assay (Fig. 7E), further extending previous observations on
proapoptotic activity of a combination of TRAIL and RSV in cancer
cells [Fulda and Debatin, 2004; Ivanov et al., 2008], while the effect
of this combination on TIG-3 normal fibroblasts was only marginal.
Taken together, the present results and previously published data
allow us to link proapoptotic effects of RSV in a combination with
TRAIL, at least partially, with suppression of anti-apoptotic
functions by NF-kB and STAT3 in melanoma cells.
Among additional suppressors of inflammation, a small
molecular inhibitor of the ATM-NF-kB/STAT3 signaling pathway,
KU-55933 (10mM), demonstrated pronounced anti-inflammatory
effects (determined by downregulation of IL6 secretion) and
upregulation of TRAIL-mediated apoptosis in human melanoma
Fig. 7. Resveratrol (RSV), a natural inhibitor of NF-kB and STAT3 activation, negatively regulates secretion of TNFa and IL6, COX-2 expression and increases TRAIL-induced
apoptosis in melanoma lines. A,B: Effects of RSV (25–100mM) on TNFa and IL6 secretion. C: Western blot analysis of COX-2 protein levels following RSV exposure. D: RSV
(50mM) suppressed oxygen consumption in melanoma cells. E: Effects of RSV, TRAIL, and their combination on clonogenic survival of melanoma cell lines. Error bars represent
mean SD (Student’s t-test, P< 0.05).
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cells (Suppl. Fig. 3) confirming our recent observations on a role
of ATM kinase activity in the regulation of apoptosis in melanoma
cells [Ivanov et al., 2009].
DISCUSSION
Since many melanoma cell lines exhibit profound resistance to
TRAIL treatment, we and others investigated the origin of this
resistance and demonstrated an upregulation of TRAIL/TRAIL-R-
mediated apoptosis in metastatic melanoma cells using different
types of co-treatment for suppression of strong anti-apoptotic
mechanisms in cancer cells [Hersey et al., 2006; Ivanov et al., 2007].
Melanoma has multifactorial etiology and, quite predictably,
different approaches should be used for successful treatment of
this disease. An interesting and potentially important difference
between melanoma lines observed in the present study was the
different levels of mitochondrial function that could probably
predict different effects of drugs targeting mitochondria. Melanoma
cells with suppressed mitochondrial function responded poorly to
sodium arsenite or other mitochondrial target drugs. This was based
on downregulation of the mitochondrial pathway of apoptotic
death, which actively required energy produced by mitochondria, in
advanced melanomas. In some cases (OM431 and SW1 melanoma
cells), an additional suppression of the mitochondrial apoptotic
pathway was based on strong downregulation of APAF1 levels,
a critical adaptor protein of this pathway [Soengas and Lowe, 2003;
Ivanov and Hei, 2006b]. We investigated a role of the proin-
flammatory response of melanoma cells via TNFa/TNFR-NF-kB-
IL6/IL6R-STAT3 pathways in regulation of apoptosis to consider
alternative approaches for treatment of metastatic melanomas.
Although a general link between inflammation and tumorigen-
esis is well established [Karin, 2009], there are many different
aspects to this problem. The focus of our study was the
proinflammatory response of metastatic melanoma cells based
on the endogenous NF-kB- and STAT3-transcriptional activation of
cytokine gene expression, establishing an autocrine loop with
further activation of NF-kB- and STAT3-dependent anti-apoptotic
genes, including COX-2 and cFLIP. We further demonstrated that
suppression of this protective loop at several points (TNFa, IKKb–
NF-kB, IL6, JAK2–STAT3, COX-2) substantially upregulated TRAIL-
induced apoptosis in melanoma cells. Unfortunately, for some
melanoma lines, even increasing apoptotic response to TRAIL still
did not achieve high levels of apoptosis. The preliminary
upregulation of TRAIL-R2/R1 (DR5/DR4) levels using different
approaches might further help to upregulate TRAIL-induced
apoptosis in these melanoma lines [Ivanov et al., 2007].
Numerous mechanisms that control either direct physical
interaction between NF-kB RelA subunit and STAT3 [Yang et al.,
2007] or extensive cross-talking between signaling pathways
targeting gene expression and activation of NF-kB and STAT3
have been elucidated in the inflammatory network, including in
cancer cells [Grivennikov and Karin, 2008]. One of the critical results
of NF-kB and STAT3 interactions in tumorigenesis also targets the
mitochondria. A deficiency of normal mitochondrial respiratory
function, but increased production of reactive oxygen species, one
of the characteristic features of the inflammatory response
[Alexeyev et al., 2004], might be frequently found in cancer cells,
which have a tendency to change their energetic metabolism from
oxidative phosphorylation to oxidative glycolysis (‘‘Warburg
effect’’) [Jones and Thompson, 2009]. Such downregulation of
mitochondrial function could be achieved via direct depletion
of mtDNA with suppression of mitochondriogenesis, as we observed
in the present study. Alternatively, transcription factors, such as NF-
kB and STAT3 could play multiple roles in the control of
mitochondrial function. By transcriptional regulation of COX-2
and iNOS, both NF-kB and STAT3 positively control ROS and NOS
production. On the other hand, via transcriptional regulation of
antioxidant enzymes, such as Mn-superoxide dismutase, NF-kB
could balance ROS levels and abrogate destructive effects of ROS
on mitochondria [Luo et al., 2005].
The present study and our previous work [Ivanov et al., 2007,
2009] provide significant understanding of the regulation of TRAIL-
mediated apoptosis in melanoma cells and will potentially foster
translational development of a new therapy for treatment of
currently therapy-resistant metastatic melanomas. This strategy
for treatment of human melanomas, which could be further used
in translational research, is based on: (i) dramatic upregulation of
surface expression of death receptor (TRAIL-R1/DR4 and TRAIL-R2/
DR5) in metastatic melanomas using ionizing radiation;
(ii) increasing sensitivity to apoptosis using inhibition (immuno-
logical, pharmacological or by specific RNAi) of the TNFa/TNFR–
NF-kB–IL-6/IL-6R–STAT3–COX2 signaling cascade in human
melanoma cells. Our study also demonstrates that dual inhibition
of NF-kB and STAT3-dependent gene expression (through small
molecular inhibitors or natural agents, such as resveratrol [Fulda
and Debatin, 2004]) was especially efficient for increasing the
TRAIL-response in some human melanoma lines.
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